These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

446 related articles for article (PubMed ID: 25655145)

  • 1. Novel psychoactive substances of interest for psychiatry.
    Schifano F; Orsolini L; Duccio Papanti G; Corkery JM
    World Psychiatry; 2015 Feb; 14(1):15-26. PubMed ID: 25655145
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel psychoactive substances (designer drugs): overview and pharmacology of modulators of monoamine signaling.
    Liechti M
    Swiss Med Wkly; 2015; 145():w14043. PubMed ID: 25588018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Stimulant and hallucinogenic novel psychoactive substances; an update.
    Schifano F; Vento A; Scherbaum N; Guirguis A
    Expert Rev Clin Pharmacol; 2023; 16(11):1109-1123. PubMed ID: 37968919
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel psychoactive substances: the pharmacology of stimulants and hallucinogens.
    Schifano F; Papanti GD; Orsolini L; Corkery JM
    Expert Rev Clin Pharmacol; 2016 Jul; 9(7):943-54. PubMed ID: 26985969
    [TBL] [Abstract][Full Text] [Related]  

  • 5. "Legal Highs"--An Emerging Epidemic of Novel Psychoactive Substances.
    Zawilska JB
    Int Rev Neurobiol; 2015; 120():273-300. PubMed ID: 26070762
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neuropharmacology of New Psychoactive Substances (NPS): Focus on the Rewarding and Reinforcing Properties of Cannabimimetics and Amphetamine-Like Stimulants.
    Miliano C; Serpelloni G; Rimondo C; Mereu M; Marti M; De Luca MA
    Front Neurosci; 2016; 10():153. PubMed ID: 27147945
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New/emerging psychoactive substances and associated psychopathological consequences.
    Schifano F; Napoletano F; Chiappini S; Guirguis A; Corkery JM; Bonaccorso S; Ricciardi A; Scherbaum N; Vento A
    Psychol Med; 2021 Jan; 51(1):30-42. PubMed ID: 31327332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New Psychoactive Substances and Suicidality: A Systematic Review of the Current Literature.
    Chiappini S; Mosca A; Miuli A; Santovito MC; Orsolini L; Corkery JM; Guirguis A; Pettorruso M; Martinotti G; Di Giannantonio M; Schifano F
    Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34204131
    [No Abstract]   [Full Text] [Related]  

  • 9. Prevalence of Novel Psychoactive Substance (NPS) Use in Patients Admitted to Drug Detoxification Treatment.
    Specka M; Kuhlmann T; Sawazki J; Bonnet U; Steinert R; Cybulska-Rycicki M; Eich H; Zeiske B; Niedersteberg A; Schaaf L; Scherbaum N
    Front Psychiatry; 2020; 11():569. PubMed ID: 32733288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. New Psychoactive Substances Intoxications and Fatalities during the COVID-19 Epidemic.
    Lo Faro AF; Berardinelli D; Cassano T; Dendramis G; Montanari E; Montana A; Berretta P; Zaami S; Busardò FP; Huestis MA
    Biology (Basel); 2023 Feb; 12(2):. PubMed ID: 36829550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Self-reported use of novel psychoactive substances in a US nationally representative survey: Prevalence, correlates, and a call for new survey methods to prevent underreporting.
    Palamar JJ; Martins SS; Su MK; Ompad DC
    Drug Alcohol Depend; 2015 Nov; 156():112-119. PubMed ID: 26377051
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro characterization of new psychoactive substances at the μ-opioid, CB1, 5HT
    Åstrand A; Guerrieri D; Vikingsson S; Kronstrand R; Green H
    Forensic Sci Int; 2020 Dec; 317():110553. PubMed ID: 33160102
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacology and adverse effects of new psychoactive substances: synthetic cannabinoid receptor agonists.
    Chung EY; Cha HJ; Min HK; Yun J
    Arch Pharm Res; 2021 Apr; 44(4):402-413. PubMed ID: 33811300
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The clinical challenges of synthetic cathinones.
    Schifano F; Napoletano F; Arillotta D; Zangani C; Gilgar L; Guirguis A; Corkery JM; Vento A
    Br J Clin Pharmacol; 2020 Mar; 86(3):410-419. PubMed ID: 31674690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of novel psychoactive drug use in Sweden based on laboratory analysis--initial experiences from the STRIDA project.
    Helander A; Beck O; Hägerkvist R; Hultén P
    Scand J Clin Lab Invest; 2013 Aug; 73(5):400-6. PubMed ID: 23692208
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A systematic review of the effects of novel psychoactive substances 'legal highs' on people with severe mental illness.
    Gray R; Bressington D; Hughes E; Ivanecka A
    J Psychiatr Ment Health Nurs; 2016 Jun; 23(5):267-81. PubMed ID: 27037639
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effects and risks associated to mephedrone and methylone in humans: A review of the preliminary evidences.
    Karila L; Billieux J; Benyamina A; Lançon C; Cottencin O
    Brain Res Bull; 2016 Sep; 126(Pt 1):61-67. PubMed ID: 26995278
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Next generation of novel psychoactive substances on the horizon - A complex problem to face.
    Zawilska JB; Andrzejczak D
    Drug Alcohol Depend; 2015 Dec; 157():1-17. PubMed ID: 26482089
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Psychoactive Substances (NPS) - a Challenge for the Addiction Treatment Services.
    Scherbaum N; Schifano F; Bonnet U
    Pharmacopsychiatry; 2017 May; 50(3):116-122. PubMed ID: 28444659
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Detection of new psychoactive substance use among emergency room patients: results from the Swedish STRIDA project.
    Helander A; Bäckberg M; Hultén P; Al-Saffar Y; Beck O
    Forensic Sci Int; 2014 Oct; 243():23-9. PubMed ID: 24726531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.